Berlin, Germany, Germantown, MD, U.S.A. and Wuhan and Beijing, China - Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), a German-American cancer molecular diagnostics company, and Wuhan Kindstar Clinical Diagnostics Co. Ltd (Kindstar), a leading Chinese clinical diagnostics company, announced today that both parties entered into a licensing and supply agreement for Epigenomics’ Epi proLung® tissue assay for the Chinese market.
Under the terms of the agreement Kindstar will commercialize the Epi proLung® assay for use in lung cancer diagnosis in China. Epigenomics will retain the responsibility to manufacture and supply the product and to provide support with respect to medical and regulatory considerations.
Noel Doheny, CEO of Epigenomics' US subsidiary, commented: "We are excited to enter into this agreement regarding our Epi proLung® tissue assay with Kindstar. The ability to leverage the established know-how and existing and well-functioning reference laboratory infrastructure of our new partner will provide a significant advantage for Epigenomics in the market introduction and technology roll-out of Epi proLung® in China. This agreement allows for a dual commercialization effort to apply Epigenomics' patented methods and its biomarker for lung cancer diagnosis in the Chinese market.”
“Epigenomics’ Epi proLung® assay fills an unmet need in current lung cancer diagnosis,” added Shiang Huang, M.D., CEO of Kindstar. “We are very pleased to add Epi proLung® to the suite of cancer testing services we offer to Chinese physicians. We look forward to collaborating with Epigenomics on this assay and to the opportunity to expand our partnership on additional tests for the Chinese market.”
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is under regulatory review by the FDA for the U.S.A. Additionally, the company markets its tissue assay for use in lung cancer diagnosis, Epi proLung®, in Europe. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.
About Kindstar
Kindstar (www.kindstarglobal.com), with laboratory facilities in Beijing, Shanghai and Wuhan, provides esoteric diagnostic testing services to hospitals and physicians in every province of China. Kindstar is the first and largest esoteric diagnostic testing business in China, providing laboratory testing services to over 3,300 Chinese hospitals, including 930 tertiary hospitals (classification for largest leading hospitals). Kindstar is becoming the partner of choice to physicians in China for advanced diagnostics in many medical specialties including hematology, oncology, infectious diseases and medical genetics.
Contact Epigenomics AG
Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse1
10178 Berlin
Tel +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
For US press inquiries:
Epigenomics, Inc.
20271 Goldenrod lane, 2nd Floor
Germantown Md., 20874
pr@epigenomics.com
Contact Kindstar
Clover Zhang
86-186-0275-6477
Clover.zhang@kindstar.com
Epigenomics AG公司与康圣环球签订Epi proLung合作协议
- 康圣环球2014年1月10日 9:44 点击：5376
德国柏林，美国，和中国武汉，北京，2014年1月9日 –Epigenomics AG（法兰克福金标准：ECX，OTC:EPGNY），一个德-美癌症分子诊断公司，与中国领先的临床诊断公司--康圣环球在今天宣布双方签订了Epi proLung®---一个用于辅助诊断早期肺癌检测的授权和供应协议。
根据协议条款，康圣环球将促进该检测项目的商业化进程以便用于在中国的肺癌诊断。Epigenomics公司也将负责向康圣环球提供产品及技术支持，并提供医学和监管方面的协助。
Epigenomics有限公司美国子公司的首席执行官--诺埃尔•多希尼表示：“我们很高兴能够与康圣环球就该项利用组织学方法辅助早期肺癌的检测签订协议。这种利用现有的专业技术结合我们合作伙伴成熟实验室的能力作为合作的基础构建，将是Epigenomics公司在中国实现技术转移和市场推广的一大优势。该协议也表明了双方致力于将Epigenomics针对肺癌检测的专利检测技术和生物标志物应用于中国市场的努力。”
Epigenomics公司的Epi proLung®检测满足目前肺癌的诊断需求，康圣环球CEO黄士昂说道：“我们非常高兴能将这种早期肺癌辅助诊断技术加入到我们肺癌检测的整套服务体系中去，一并提供给中国医生。我们期待这一合作，也期待有机会能扩大与Epigenomics公司的合作并为中国市场引进更多的检测项目。
关于Epigenomics：
Epigenomics是一家分子诊断公司，开发和供应各种癌症检测产品。该公司的产品帮助医生更准确地进行癌症早期诊断，改善患者的预后。Epigenomics的主导产品，Epi proColon®是一种通过对血液的研究辅助预测早期大肠癌的检测，目前在欧洲销售，并正在接受美国FDA的申报审查。此外，该公司销售其肺癌的检测，将Epi proColon®运用于组织诊断。该公司的技术和产品已经通过了全球领先的企业诊断和检测实验室的检测，并与他们开展了密切的合作。Epigenomics是一个在欧洲和美国均拥有业务的国际公司。
关于康圣环球
康圣环球在北京、上海和武汉三地拥有独立实验室，为中国所有省市的医院和医生提供专业临床诊断检测服务，康圣环球是中国首家和最大的高端医学特检服务集团，它的客户遍布全中国3300家医院，包括1100家三甲医院。康圣环球由于在许多医学专业，如：血液学、肿瘤学、传染病和医学遗传学方面提供先进的诊断，它正成为中国医生首选的合作伙伴。
Epigenomics signs licensing and supply agreement with Kindstar for Epi proLung in China
09.01.2014
联系邮箱：kefu@labbase.net
版权与免责声明
- 凡本网注明“来源：来宝网”的所有作品，版权均属于来宝网，转载请必须注明来宝网， //www.next-search.com，违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品，目的在于传递更多信息，并不代表本网赞同其观点或证实其内容的真实性，不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时，必须保留本网注明的作品来源，并自负版权等法律责任。
- 如涉及作品内容、版权等问题，请在作品发表之日起一周内与本网联系，否则视为放弃相关权利。
